

Ana Isabel Tomaz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3472529/publications.pdf>

Version: 2024-02-01

50
papers

2,269
citations

136885

32
h-index

206029

48
g-index

51
all docs

51
docs citations

51
times ranked

2329
citing authors

#	ARTICLE	IF	CITATIONS
1	New iron(III) anti-cancer aminobisphenolate/phenanthroline complexes: Enhancing their therapeutic potential using nanoliposomes. <i>International Journal of Pharmaceutics</i> , 2022, 623, 121925.	2.6	6
2	Ruthenium and iron metallodrugs: new inorganic and organometallic complexes as prospective anticancer agents. , 2021, , 223-276.		4
3	Half-Sandwich Ru(<i>p</i> -cymene) Compounds with Diphosphanes: <i>In Vitro</i> and <i>In Vivo</i> Evaluation As Potential Anticancer Metallodrugs. <i>Inorganic Chemistry</i> , 2021, 60, 2914-2930.	1.9	18
4	Unprecedented collateral sensitivity for cisplatin-resistant lung cancer cells presented by new ruthenium organometallic compounds. <i>Inorganic Chemistry Frontiers</i> , 2021, 8, 1983-1996.	3.0	20
5	Interaction with Blood Proteins of a Ruthenium(II) Nitrofuryl Semicarbazone Complex: Effect on the Antitumoral Activity. <i>Molecules</i> , 2019, 24, 2861.	1.7	15
6	Experimental data on novel Fe(III)-complexes containing phenanthroline derivatives for their anticancer properties. <i>Data in Brief</i> , 2019, 27, 104548.	0.5	2
7	May iron(III) complexes containing phenanthroline derivatives as ligands be prospective anticancer agents?. <i>European Journal of Medicinal Chemistry</i> , 2019, 176, 492-512.	2.6	35
8	New ternary iron(III) aminobisphenolate hydroxyquinoline complexes as potential therapeutic agents. <i>Dalton Transactions</i> , 2019, 48, 8702-8716.	1.6	17
9	Antitumour and Toxicity Evaluation of a Ru(II)-Cyclopentadienyl Complex in a Prostate Cancer Model by Imaging Tools. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 19, 1262-1275.	0.9	13
10	Ru ^{II} (<i>p</i> -cymene) Compounds as Effective and Selective Anticancer Candidates with No Toxicity <i>In Vivo</i> . <i>Inorganic Chemistry</i> , 2018, 57, 13150-13166.	1.9	52
11	Studies on the mechanism of action of antitumor bis(aminophenolate) ruthenium(III) complexes. <i>Journal of Inorganic Biochemistry</i> , 2017, 168, 27-37.	1.5	23
12	<i>In Vivo</i> Performance of a Ruthenium-cyclopentadienyl Compound in an Orthotopic Triple Negative Breast Cancer Model. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2017, 17, 126-136.	0.9	25
13	Tracking antitumor metallodrugs: promising agents with the Ru(II)- and Fe(II)-cyclopentadienyl scaffolds. <i>Future Medicinal Chemistry</i> , 2016, 8, 527-544.	1.1	53
14	Novel ruthenium(II) cyclopentadienyl thiosemicarbazone compounds with antiproliferative activity on pathogenic trypanosomatid parasites. <i>Journal of Inorganic Biochemistry</i> , 2015, 153, 306-314.	1.5	35
15	A new ruthenium cyclopentadienyl azole compound with activity on tumor cell lines and trypanosomatid parasites. <i>Journal of Coordination Chemistry</i> , 2015, 68, 2923-2937.	0.8	37
16	The key role of coligands in novel ruthenium(II)-cyclopentadienyl bipyridine derivatives: Ranging from non-cytotoxic to highly cytotoxic compounds. <i>Journal of Inorganic Biochemistry</i> , 2015, 150, 148-159.	1.5	36
17	The effect of phosphate on the nuclease activity of vanadium compounds. <i>Journal of Inorganic Biochemistry</i> , 2015, 147, 165-176.	1.5	8
18	Effect of the Metal Ion on the anti <i>T. cruzi</i> Activity and Mechanism of Action of 5-Nitrofuryl-Containing Thiosemicarbazone Metal Complexes. <i>European Journal of Inorganic Chemistry</i> , 2014, 2014, 4677-4689.	1.0	26

#	ARTICLE	IF	CITATIONS
19	Anticancer activity of structurally related ruthenium(II) cyclopentadienyl complexes. <i>Journal of Biological Inorganic Chemistry</i> , 2014, 19, 853-867.	1.1	52
20	Insights into the mechanisms underlying the antiproliferative potential of a Co(II) coordination compound bearing 1,10-phenanthroline-5,6-dione: DNA and protein interaction studies. <i>Journal of Biological Inorganic Chemistry</i> , 2014, 19, 787-803.	1.1	33
21	Interaction of vanadium(IV) with human serum apo-transferrin. <i>Journal of Inorganic Biochemistry</i> , 2013, 121, 187-195.	1.5	72
22	Important cytotoxicity of novel iron(II) cyclopentadienyl complexes with imidazole based ligands. <i>Journal of Inorganic Biochemistry</i> , 2013, 129, 1-8.	1.5	32
23	A novel VIVO π -pyrimidinone complex: synthesis, solution speciation and human serum protein binding. <i>Dalton Transactions</i> , 2013, 42, 11841.	1.6	38
24	New polydentate Ru(III)-Salan complexes: Synthesis, characterization, anti-tumour activity and interaction with human serum proteins. <i>Inorganica Chimica Acta</i> , 2013, 394, 616-626.	1.2	31
25	Screening organometallic binuclear thiosemicarbazone ruthenium complexes as potential anti-tumour agents: cytotoxic activity and human serum albumin binding mechanism. <i>Dalton Transactions</i> , 2013, 42, 7131.	1.6	83
26	Cellular Uptake Mechanisms of an Antitumor Ruthenium Compound: The Endosomal/Lysosomal System as a Target for Anticancer Metal-Based Drugs. <i>Microscopy and Microanalysis</i> , 2013, 19, 1122-1130.	0.2	35
27	[Ru(II)(π -5-C ₅ H ₅)(bipy)(PPh ₃)] ⁺ , a promising large spectrum antitumor agent: Cytotoxic activity and interaction with human serum albumin. <i>Journal of Inorganic Biochemistry</i> , 2012, 117, 261-269.	1.5	72
28	Evaluation of the binding of oxovanadium(IV) to human serum albumin. <i>Dalton Transactions</i> , 2012, 41, 6477.	1.6	71
29	VIVO and Cu(II) complexation by ligands based on pyridine nitrogen donors. <i>Dalton Transactions</i> , 2012, 41, 12824.	1.6	55
30	Vanadium(IV) and π -V(IV) Complexes of Reduced Schiff Bases Derived from Aromatic α -Hydroxyaldehydes and Tyrosine Derivatives. <i>European Journal of Inorganic Chemistry</i> , 2011, 2011, 694-708.	1.0	14
31	Searching for gallium bioactive compounds: Gallium(III) complexes of tridentate salicylaldehyde semicarbazone derivatives. <i>Polyhedron</i> , 2011, 30, 1360-1366.	1.0	36
32	Transport of Therapeutic Vanadium and Ruthenium Complexes by Blood Plasma Components. <i>Current Medicinal Chemistry</i> , 2010, 17, 3701-3738.	1.2	187
33	Design of vanadium mixed-ligand complexes as potential anti-protozoa agents. <i>Journal of Inorganic Biochemistry</i> , 2009, 103, 609-616.	1.5	92
34	Vanadium compounds as therapeutic agents: Some chemical and biochemical studies. <i>Journal of Inorganic Biochemistry</i> , 2009, 103, 601-608.	1.5	68
35	DNA cleavage activity of VIVO(acac) ₂ and derivatives. <i>Journal of Inorganic Biochemistry</i> , 2009, 103, 622-632.	1.5	59
36	A novel vanadyl complex with a polypyridyl DNA intercalator as ligand: A potential anti-protozoa and anti-tumor agent. <i>Journal of Inorganic Biochemistry</i> , 2009, 103, 1386-1394.	1.5	85

#	ARTICLE	IF	CITATIONS
37	Electronic Properties of a Cytosine Decavanadate: Toward a Better Understanding of Chemical and Biological Properties of Decavanadates. <i>Inorganic Chemistry</i> , 2009, 48, 9742-9753.	1.9	37
38	Biospeciation of various antidiabetic VIVO compounds in serum. <i>Dalton Transactions</i> , 2009, , 2428.	1.6	109
39	Vanadium (IV and V) Complexes of Reduced Schiff Bases Derived from the Reaction of Aromatic-Hydroxyaldehydes and Diamines Containing Carboxyl Groups. <i>European Journal of Inorganic Chemistry</i> , 2006, 2006, 3595-3606.	1.0	19
40	Uptake and metabolic effects of insulin mimetic oxovanadium compounds in human erythrocytes. <i>Journal of Inorganic Biochemistry</i> , 2005, 99, 2328-2339.	1.5	65
41	Interaction and Lipid-Induced Conformation of Two Cecropin~Melittin Hybrid Peptides Depend on Peptide and Membrane Composition. <i>Journal of Physical Chemistry B</i> , 2005, 109, 17311-17319.	1.2	49
42	Interactions of VO(IV) with oligopeptides. <i>Coordination Chemistry Reviews</i> , 2003, 237, 123-133.	9.5	49
43	Preparation and characterisation of vanadium complexes derived from salicylaldehyde or pyridoxal and sugar derivatives. <i>Inorganica Chimica Acta</i> , 2003, 356, 121-132.	1.2	37
44	Molecular modelling studies of N-salicylideneamino acidato complexes of oxovanadium(IV). Molecular and crystal structure of a new dinuclear VO(IV)-O-VOL mixed valence complex. <i>Dalton Transactions RSC</i> , 2002, , 4407.	2.3	72
45	The systems VO ₂ ⁺ -glutathione and related ligands: a potentiometric and spectroscopic study. <i>Journal of Biological Inorganic Chemistry</i> , 2002, 7, 225-240.	1.1	49
46	Thiolate-S as anchoring donor in the binary and ternary VO(IV) complexes of mercaptopropionylglycine. <i>Inorganica Chimica Acta</i> , 2002, 339, 119-128.	1.2	32
47	The system VO ₂ ⁺⁺ -oxidized glutathione: a potentiometric and spectroscopic study. <i>Journal of Inorganic Biochemistry</i> , 2001, 84, 259-270.	1.5	56
48	Oxovanadium(IV) complexes with aromatic aldehydes. <i>Journal of Inorganic Biochemistry</i> , 2000, 80, 35-39.	1.5	55
49	Preparation and characterisation of new oxovanadium(IV) Schiff base complexes derived from amino acids and aromatic o-hydroxyaldehydes. <i>Inorganica Chimica Acta</i> , 1999, 293, 1-11.	1.2	88
50	X-ray characterization of an unusual product obtained from [VO(Sal~Phe)(H ₂ O)] in H ₂ Opyridine solutions. <i>Polyhedron</i> , 1998, 17, 3269-3274.	1.0	9